CytomX Therapeutics Target of Unusually Large Options Trading (NASDAQ:CTMX)

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 20,170 call options on the company. This is an increase of approximately 1,392% compared to the typical volume of 1,352 call options.

Analysts Set New Price Targets

CTMX has been the topic of several recent research reports. Cantor Fitzgerald raised their price target on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Piper Sandler boosted their price target on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Wedbush restated an “outperform” rating and set a $6.00 price target on shares of CytomX Therapeutics in a research report on Friday, November 7th. Barclays lifted their price objective on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Finally, Guggenheim started coverage on shares of CytomX Therapeutics in a research note on Tuesday, January 20th. They set a “buy” rating and a $10.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Institutional Investors Weigh In On CytomX Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CTMX. Wells Fargo & Company MN raised its holdings in shares of CytomX Therapeutics by 83.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares in the last quarter. Farther Finance Advisors LLC acquired a new position in CytomX Therapeutics in the third quarter worth approximately $25,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in CytomX Therapeutics in the fourth quarter worth approximately $35,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of CytomX Therapeutics in the third quarter valued at $34,000. Finally, May Hill Capital LLC bought a new position in shares of CytomX Therapeutics in the fourth quarter valued at $46,000. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Stock Performance

Shares of NASDAQ CTMX opened at $5.07 on Thursday. CytomX Therapeutics has a 1 year low of $0.40 and a 1 year high of $6.35. The firm has a market cap of $859.01 million, a P/E ratio of 12.68 and a beta of 2.44. The stock has a fifty day moving average price of $5.11 and a two-hundred day moving average price of $3.89.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.